-
-
-
-
-
-
-
GSK to acquire RAPT Therapeutics for $2.2 billion in food allergy deal
-
-
-
-
-
-
-
GSK (GSK) to acquire efimosfermin
-
-
-
-
-
-
-
ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024
-
-
-
-
-
-
-
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
-
-
-
-
-
-
-
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
-
-
-
-
-
-
-
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
-
-
-
-
-
-
-
GSK to spend up to $3.3 billion on Affinivax to boost vaccines roster
-
1,177,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

